McMahan ZH, et al. - In patients with scleroderma (SSc), experts gauged the relationship of anti-RNPC3 antibodies with certain gastrointestinal (GI) tract complications. They screened the sera from SSc patients with or without severe GI dysfunction (total parenteral nutrition-dependence) from the Johns Hopkins Scleroderma Center for anti-RNPC3 antibodies. Findings suggested the higher likelihood of patients with SSc and anti-RNPC3 antibodies to be male, black, and to have moderate to severe GI disease and interstitial lung disease. In the Pittsburgh cohort, 36% of anti-RNPC3 positive patients vs 15% of anti-RNPC3 negative patients presented with moderate to severe GI dysfunction (Medsger GI score ≥2).